Paradigm Health Acquires Flatiron’s Research Unit, Forms Strategic Partnership

Paradigm Health has announced it will acquire Flatiron Health’s Clinical Research Business, a move that brings together the largest tech-enabled U.S. oncology research network with Paradigm’s end-to-end, AI-powered clinical trial platform. The deal includes a multi-year strategic partnership between the two companies aimed at expanding clinical trial access, improving trial efficiency, and strengthening the connection between research and routine care for patients across the United States and globally.

Through the acquisition, Paradigm Health will add more than 25 academic medical centers, numerous health systems, and nearly 100 community oncology practices to its network—reaching over 2.4 million patients nationwide. The long-term collaboration will integrate Flatiron’s established clinical research solutions and site network with Paradigm’s technology platform, enabling more inclusive and efficient trials without requiring additional infrastructure from participating sites. Together, the organizations aim to expand U.S. research capacity by bringing clinical trials directly into community care settings.

Paradigm CEO Kent Thoelke said the combined platform will help ensure clinical research reflects the diversity of patients who need new therapies, while Flatiron CEO Nathan Hubbard emphasized that the partnership strengthens the clinical research ecosystem by pairing Paradigm’s AI capabilities with Flatiron’s trusted oncology network. The collaboration also includes native integration of Paradigm’s tools into Flatiron’s OncoEMR®, new capability development, and expanded trial support for Flatiron’s provider network.

The deal further deepens Paradigm’s ties to the biopharmaceutical industry, enabling the company to serve 15 of the top 20 global biopharma firms and increasing capacity for embedded Phase IV trials—accelerating real-world evidence generation after drug approval. Both organizations reaffirmed a shared mission to make clinical trials more representative, efficient, and accessible while supporting global priorities to modernize research and broaden participation. Financial terms were not disclosed.